Background: The treatment paradigm for HER2+ metastatic breast cancer (MBC) patients with brain metastases (BM) has shifted from local therapies to a multi-disciplinary approach including ...

Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: A multicenter real-world study.. JCO 43 , e13005-e13005 (2025). DOI: 10.1200 ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

In the multicenter, open-label DESTINY-Breast09 study, patients with HER2-positive metastatic or advanced breast cancer were randomly assigned 1:1:1 to receive Enhertu at 5.4 milligram per kilogram ...

DESTINY-Breast09 is a multicenter open-label three-arm study of 1,157 patients with HER2-positive advanced or metastatic breast cancer. They are disease free for >6 months from their last ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Neuroimaging evidence enhances understanding of the subcortex’s role in the neural mechanisms of working memory updating, providing new insights into midbrain function.

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...

Zanidatamab, a bispecific antibody for HER2+ biliary tract cancer, receives conditional approval in China, unlocking $20 million milestone.

These results support T-DXd as a global second-line standard of care for HER2-positive gastric and GE cancer in an earlier-line setting." The study was published simultaneously in the New England ...